Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azeliragon in Mild Alzheimer's Disease (STEADFAST)
NCT02080364Phase 3Terminated
- Sponsor
- vTv Therapeutics
- Start
- Apr 2015
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial of azeliragon in Alzheimer's disease (AD), sponsored by vTv Therapeutics. Started Apr 2015; status: terminated.
02
Drugs
azeliragon
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02080364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02080364.